Bristol-Myers Granted Right to Buy Promedior
August 31 2015 - 9:40AM
Dow Jones News
Bristol-Myers Squibb Co. said Monday that it has been granted
the exclusive right to buy privately held Promedior Inc. and its
experimental fibrosis treatment for up to $1.25 billion.
Under the terms of the agreement, Bristol-Myers will pay $150
million in cash up front for the right to buy Promedior.
Bristol-Myers can exercise that right after Promedior completes
either of two phase-two trials for the treatment PRM-151.
Promedior expects to begin clinical trials of the treatment for
idiopathic pulmonary fibrosis and myelofibrosis patients in the
coming weeks. PRM-151 has been granted fast-track designation and
orphan designation.
Fibrosis is associated with several rare diseases and illnesses
such as age-related macular degeneration and solid tumors. Fibrosis
occurs when healthy tissue is replaced with scar tissue, which can
compromise function and lead to organ failure.
Bristol-Myers said the drug will complement its early-stage
fibrosis portfolio. The company last year signed an option
agreement to buy Galecto Biotech AB, a company with an inhaled
inhibitor for the treatment of idiopathic pulmonary fibrosis.
Write to Chelsey Dulaney at Chelsey.Dulaney@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
August 31, 2015 09:25 ET (13:25 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024